Literature DB >> 26471690

Progressing Toward a Cohesive Pediatric 18F-FDG PET/MR Protocol: Is Administration of Gadolinium Chelates Necessary?

Christopher Klenk1, Rakhee Gawande1, Vy Thao Tran1, Jennifer Trinh Leung1, Kevin Chi1, Daniel Owen1, Sandra Luna-Fineman2, Kathleen M Sakamoto2, Alex McMillan1, Andy Quon1, Heike E Daldrup-Link3.   

Abstract

UNLABELLED: With the increasing availability of integrated PET/MR scanners, the utility and need for MR contrast agents for combined scans is questioned. The purpose of our study was to evaluate whether administration of gadolinium chelates is necessary for evaluation of pediatric tumors on (18)F-FDG PET/MR images.
METHODS: First, in 119 pediatric patients with primary and secondary tumors, we used 14 diagnostic criteria to compare the accuracy of several MR sequences: unenhanced T2-weighted fast spin-echo imaging; unenhanced diffusion-weighted imaging; and-before and after gadolinium chelate contrast enhancement-T1-weighted 3-dimensional spoiled gradient echo LAVA (liver acquisition with volume acquisition) imaging. Next, in a subset of 36 patients who had undergone (18)F-FDG PET within 3 wk of MRI, we fused the PET images with the unenhanced T2-weighted MR images (unenhanced (18)F-FDG PET/MRI) and the enhanced T1-weighted MR images (enhanced (18)F-FDG PET/MRI). Using the McNemar test, we compared the accuracy of the two types of fused images using the 14 diagnostic criteria. We also evaluated the concordance between (18)F-FDG avidity and gadolinium chelate enhancement. The standard of reference was histopathologic results, surgical notes, and follow-up imaging.
RESULTS: There was no significant difference in diagnostic accuracy between the unenhanced and enhanced MR images. Accordingly, there was no significant difference in diagnostic accuracy between the unenhanced and enhanced (18)F-FDG PET/MR images. (18)F-FDG avidity and gadolinium chelate enhancement were concordant in 30 of the 36 patients and 106 of their 123 tumors.
CONCLUSION: Gadolinium chelate administration is not necessary for accurate diagnostic characterization of most solid pediatric malignancies on (18)F-FDG PET/MR images, with the possible exception of focal liver lesions.
© 2016 by the Society of Nuclear Medicine and Molecular Imaging, Inc.

Entities:  

Keywords:  18FDG-PET; MR contrast utility; PET-MR fusion; PET/MR; pediatric oncology

Mesh:

Substances:

Year:  2015        PMID: 26471690      PMCID: PMC4703553          DOI: 10.2967/jnumed.115.161646

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  37 in total

1.  Orbit, skull base, and pharynx: contrast-enhanced fat suppression MR imaging.

Authors:  J A Barakos; W P Dillon; W M Chew
Journal:  Radiology       Date:  1991-04       Impact factor: 11.105

Review 2.  Neuroblastoma imaging.

Authors:  S Ley; J Ley-Zaporozhan; P Günther; H E Deubzer; O Witt; J-P Schenk
Journal:  Rofo       Date:  2010-12-17

3.  F-18 FDG PET/CT evaluation of osseous and soft tissue sarcomas.

Authors:  Andrei Iagaru; Andrew Quon; I Ross McDougall; Sanjiv S Gambhir
Journal:  Clin Nucl Med       Date:  2006-12       Impact factor: 7.794

Review 4.  Neuroimaging in neuro-oncology.

Authors:  Soonmee Cha
Journal:  Neurotherapeutics       Date:  2009-07       Impact factor: 7.620

5.  Evaluation of neuroendocrine liver metastases: a comparison of dynamic contrast-enhanced magnetic resonance imaging and positron emission tomography/computed tomography.

Authors:  Marco Armbruster; Steven Sourbron; Alexander Haug; Christoph J Zech; Michael Ingrisch; Christoph J Auernhammer; Konstantin Nikolaou; Philipp M Paprottka; Carsten Rist; Maximilian F Reiser; Wieland H Sommer
Journal:  Invest Radiol       Date:  2014-01       Impact factor: 6.016

6.  Diffusion-weighted MRI (DWI) in the oncology patient: value of breathhold DWI compared to unenhanced and gadolinium-enhanced MRI.

Authors:  Russell N Low; Jonathan Gurney
Journal:  J Magn Reson Imaging       Date:  2007-04       Impact factor: 4.813

Review 7.  Imaging of malignant tumours of the long bones in children: monitoring response to neoadjuvant chemotherapy and preoperative assessment.

Authors:  Hervé Brisse; Liliane Ollivier; Véronique Edeline; Hélène Pacquement; Jean Michon; Christophe Glorion; Sylvia Neuenschwander
Journal:  Pediatr Radiol       Date:  2004-04-22

8.  Quantitative Evaluation of Segmentation- and Atlas-Based Attenuation Correction for PET/MR on Pediatric Patients.

Authors:  Ilja Bezrukov; Holger Schmidt; Sergios Gatidis; Frédéric Mantlik; Jürgen F Schäfer; Nina Schwenzer; Bernd J Pichler
Journal:  J Nucl Med       Date:  2015-05-07       Impact factor: 10.057

9.  Value of dynamic contrast-enhanced MRI and correlation with tumor angiogenesis in bladder cancer.

Authors:  Nermin Tuncbilek; Mustafa Kaplan; Semsi Altaner; Irfan H Atakan; Necdet Süt; Osman Inci; Mustafa Kemal Demir
Journal:  AJR Am J Roentgenol       Date:  2009-04       Impact factor: 3.959

10.  PET/MR in children. Initial clinical experience in paediatric oncology using an integrated PET/MR scanner.

Authors:  Franz Wolfgang Hirsch; Bernhard Sattler; Ina Sorge; Lars Kurch; Adrian Viehweger; Lutz Ritter; Peter Werner; Thies Jochimsen; Henryk Barthel; Uta Bierbach; Holger Till; Osama Sabri; Regine Kluge
Journal:  Pediatr Radiol       Date:  2013-01-11
View more
  7 in total

1.  Accuracy of pre-contrast imaging in abdominal magnetic resonance imaging of pediatric oncology patients.

Authors:  Faizah Mohd Zaki; Rahim Moineddin; Ronald Grant; Govind B Chavhan
Journal:  Pediatr Radiol       Date:  2016-07-12

2.  How PET/MR Can Add Value For Children With Cancer.

Authors:  Heike Daldrup-Link
Journal:  Curr Radiol Rep       Date:  2017-02-21

3.  Prognostic Value of Hybrid PET/MR Imaging in Patients with Differentiated Thyroid Cancer.

Authors:  Leandra Piscopo; Carmela Nappi; Fabio Volpe; Valeria Romeo; Emanuele Nicolai; Rosj Gallicchio; Alessia Giordano; Giovanni Storto; Leonardo Pace; Carlo Cavaliere; Marco Salvatore; Alberto Cuocolo; Michele Klain
Journal:  Cancers (Basel)       Date:  2022-06-15       Impact factor: 6.575

4.  How to Provide Gadolinium-Free PET/MR Cancer Staging of Children and Young Adults in Less than 1 h: the Stanford Approach.

Authors:  Anne M Muehe; Ashok J Theruvath; Lillian Lai; Maryam Aghighi; Andrew Quon; Samantha J Holdsworth; Jia Wang; Sandra Luna-Fineman; Neyssa Marina; Ranjana Advani; Jarrett Rosenberg; Heike E Daldrup-Link
Journal:  Mol Imaging Biol       Date:  2018-04       Impact factor: 3.488

5.  Applying Amide Proton Transfer MR Imaging to Hybrid Brain PET/MR: Concordance with Gadolinium Enhancement and Added Value to [18F]FDG PET.

Authors:  Hongzan Sun; Jun Xin; Jinyuan Zhou; Zaiming Lu; Qiyong Guo
Journal:  Mol Imaging Biol       Date:  2018-06       Impact factor: 3.488

6.  An international expert opinion statement on the utility of PET/MR for imaging of skeletal metastases.

Authors:  Jad S Husseini; Bárbara Juarez Amorim; Angel Torrado-Carvajal; Vinay Prabhu; David Groshar; Lale Umutlu; Ken Herrmann; Lina García Cañamaque; José Ramón García Garzón; William E Palmer; Pedram Heidari; Tiffany Ting-Fang Shih; Jacob Sosna; Cristina Matushita; Juliano Cerci; Marcelo Queiroz; Valdair Francisco Muglia; Marcello H Nogueira-Barbosa; Ronald J H Borra; Thomas C Kwee; Andor W J M Glaudemans; Laura Evangelista; Marco Salvatore; Alberto Cuocolo; Andrea Soricelli; Christian Herold; Andrea Laghi; Marius Mayerhoefer; Umar Mahmood; Ciprian Catana; Heike E Daldrup-Link; Bruce Rosen; Onofrio A Catalano
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-02-22       Impact factor: 9.236

7.  Are Gadolinium-Enhanced MR Sequences Needed in Simultaneous 18F-FDG-PET/MRI for Tumor Delineation in Head and Neck Cancer?

Authors:  N Pyatigorskaya; R De Laroche; G Bera; A Giron; C Bertolus; G Herve; E Chambenois; S Bergeret; D Dormont; M Amor-Sahli; A Kas
Journal:  AJNR Am J Neuroradiol       Date:  2020-09-24       Impact factor: 4.966

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.